Showing results (171-180 of 392) with videos related to
Sort By:
Pageof 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2022
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and VenetoclaxMoritz Fürstenau, Jonathan Weiss, Adam Giza, et al.Cancer Immunology, Immunotherapy : CII|April 18, 2020
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potentialMoritz Bewarder, Gerhard Held, Lorenz Thurner, et al.British Journal of Haematology|August 16, 2005
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II studyMark Ringhoffer, Norbert Blumstein, Bernd Neumaier, et al.Genome Research|September 12, 2023
Nucleosome repositioning in chronic lymphocytic leukemiaKristan V Piroeva, Charlotte McDonald, Charalampos Xanthopoulos, et al.Intensive Care Medicine Experimental|September 3, 2021
Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019Vadim Lesan, Moritz Bewarder, Carlos Metz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factorsDirk Kienle, Tiemo Katzenberger, German Ott, et al.Cancer Research|November 17, 2006
Molecular imaging of proliferation in malignant lymphomaAndreas K Buck, Martin Bommer, Stephan Stilgenbauer, et al.European Journal of Haematology|November 19, 2016
Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trialOthman Al-Sawaf, Kirsten Fischer, Carmen D Herling, et al.Haematologica|March 18, 2021
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patientsJohannes Bloehdorn, Julia Krzykalla, Karlheinz Holzmann, et al.Cancer|March 21, 2013
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemiaGeorg Hopfinger, Raymonde Busch, Natali Pflug, et al.Pageof 40